| Li |
| Active, not recruiting | 3 | 41 | Europe, Canada, Japan, US, RoW | Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO) | Swedish Orphan Biovitrum | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 06/24 | 09/25 | | |
NCT06683651: A Study in Chinese Patients With Acquired Blepharoptosis |
|
|
| Recruiting | 3 | 180 | RoW | STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800 | Santen Pharmaceutical Co., Ltd. | Blepharoptosis | 06/26 | 06/26 | | |
NCT05751967: Fenofibrate Combined with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | RoW | Placebo Combined With Ursodeoxycholic Acid, UDCA 13-15mg/kg/d, Fenofibrate Combined With Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT06174402: Fenofibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis |
|
|
| Recruiting | 2/3 | 184 | RoW | Fenofibrate, Placebo, UDCA | Han Ying | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
NCT05749822: Fenofibrate for Compensated Cirrhosis Patients with Primary Biliary Cholangitis |
|
|
| Recruiting | 2/3 | 104 | RoW | Fenofibrate 200mg, Placebo, UDCA | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT05527912: A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy |
|
|
| Recruiting | 2 | 45 | RoW | Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy, RCZ WITH CHOP | Sun Yat-sen University | Double Express Diffuse Large B-cell Lymphoma | 09/24 | 12/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
NCT06302608: Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy |
|
|
| Active, not recruiting | 1 | 6 | RoW | NGGT001 | Xiamen Ophthalmology Center Affiliated to Xiamen University | Bietti's Crystalline Dystrophy | 05/24 | 05/28 | | |
| Recruiting | 1 | 60 | RoW | BT02 monoclonal antibody injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06169449: Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment |
|
|
| Recruiting | N/A | 240 | RoW | Weight management--diet, Weight management--exercise, Weight management--accompany, Weight management--refresh, Control group | Peking University People's Hospital | Endometrium Cancer | 12/24 | 12/24 | | |
CONCORDE, NCT06127420: Comprehensive Assessment on Diagnostic and Prognostic Performance of Coronary Physiological Indices |
|
|
| Active, not recruiting | N/A | 3000 | RoW | coronary physiological indices | Shanghai Zhongshan Hospital | Coronary Artery Disease | 05/24 | 11/24 | | |
EXPECT, NCT04375319: OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS) |
|
|
| Recruiting | N/A | 60 | RoW | OCT, optical coherence tomography | Xuzhou Third People's Hospital, Shandong Jiwei Medical Products Co., Ltd | Unstable Anginas, Non ST Segment Elevation Myocardial Infarction | 12/23 | 12/23 | | |
NCT06202807: Effect of Intermittent Oro-esophageal Tube vs. Nasogastric Tube on Feeding Amount in Stroke Patients |
|
|
| Withdrawn | N/A | 80 | RoW | Intermittent Oro-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy | Zeng Changhao, The First Affiliated Hospital of Zhengzhou University | Ischemic Stroke | 04/24 | 04/24 | | |
| Withdrawn | N/A | 80 | RoW | Rehabilitation therapy, Stellate ganglion block | Zeng Changhao, The First Affiliated Hospital of Zhengzhou University | Traumatic Brain Injury | 04/24 | 05/24 | | |
| Withdrawn | N/A | 80 | RoW | Routine therapy, Stellate ganglion block | Zeng Changhao, The First Affiliated Hospital of Zhengzhou University | Autistic Disorder | 05/24 | 05/24 | | |
NCT06271395: Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction |
|
|
| Recruiting | N/A | 30 | RoW | Injectable Type A Botulinum Toxin, Botulinum Toxin Injection | Zeng Changhao | Cricopharyngeal Achalasia | 10/24 | 10/24 | | |
IOE-Xinli, NCT06265805: Effect of Different Feeding Modes on Psychological Condition and Experience in Stroke Patients |
|
|
| Recruiting | N/A | 80 | RoW | comprehensive rehabilitation therapy, Intermittent Oro-esophageal Tube Feeding, Nasogastric Tube Feeding | Zeng Changhao, The First Affiliated Hospital of Zhengzhou University | Ischemic Stroke | 12/24 | 12/24 | | |
NCT06020690: A Clinical Study to Evaluate the Safety and Effectiveness of Novabel Bioabsorbable Steroid-releasing Stent for the Chronic Sinusitis |
|
|
| Recruiting | N/A | 93 | RoW | bioabsorbable steroid-releasing stent, functional endoscopic sinus surgery | Enlight Medical Technologies (Shanghai) Co., Ltd | Chronic Sinusitis | 09/24 | 09/25 | | |
ALTER-BC-005, NCT06734533: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . |
|
|
| Recruiting | N/A | 80 | RoW | Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc | Hunan Cancer Hospital | HR+ Breast Cancer | 12/25 | 12/25 | | |
NCT06761534: Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients |
|
|
| Not yet recruiting | N/A | 678 | RoW | Screening of comprehensive geriatic assessment., the G8 assessment, Comprehensive Geriatric Assessment (CGA) | Sichuan Cancer Hospital and Research Institute | Geriatric Assessment, Geriatric Patients, Patients with Cancer, Assessment Tool | 12/25 | 12/25 | | |
NCT05714566: Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients |
|
|
| Recruiting | N/A | 100 | RoW | Clostridioides difficile toxin detection | RenJi Hospital | Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia | 06/24 | 12/24 | | |
